RecruitingPhase 2NCT06444399
Deucravacitinib (BMS-986165) for Pityriasis Rubra Pilaris
Studying Pityriasis rubra pilaris
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Mayo Clinic
- Principal Investigator
- Aaron Mangold, MD, M.DMayo Clinic
- Intervention
- Deucravacitinib(drug)
- Enrollment
- 12 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2024 – 2026
Study locations (1)
- Mayo Clinic in Arizona, Scottsdale, Arizona, United States
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06444399 on ClinicalTrials.gov